Crossmark

Optical Genome Mapping in MDS and AML as tool for structural variant profiling—comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”

Crossref DOI link: https://doi.org/10.1038/s41375-022-01763-2

Published Online: 2022-11-24

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vangala, Deepak B. https://orcid.org/0000-0002-4175-5683
Nilius-Eliliwi, Verena

Gerding, Wanda M. https://orcid.org/0000-0002-3858-9872
Schroers, Roland https://orcid.org/0000-0003-2744-5491
Nguyen, Huu Phuc
Funding

Funding for this research was provided by:

Female Clinician Scientist program of Ruhr-Univeristy Bochum, German, Grant number K147-21
License Information

Text and Data Mining valid from 2022-11-24

Version of Record valid from 2022-11-24
More Information

Article History

Received: 19 October 2022

Revised: 3 November 2022

Accepted: 9 November 2022

First Online: 24 November 2022

Competing interests

: DBV received speaker’s honoraria from Roche, BMS, Pfizer, and Falk foundation, consultant’s honoraria from Pfizer, Bristol Myers Squibb, and Gilead and travel support and congress registration fees from Gilead, Celgene, and Abbvie. VN-E received travel support and congress registration fees from Jazz Pharmaceuticals. The other authors do not report any conflicts of interest.

Document is current

Any future updates will be listed below